Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-09-09 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
PT027 PhIII asthma trials met primary endpoints
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated 09 September 2021, indicating it is a regulatory announcement disseminated via the RNS service (London Stock Exchange). The content details positive high-level results from Phase III clinical trials (MANDALA and DENALI) for a drug candidate (PT027). This type of announcement, reporting significant clinical trial outcomes and business updates via a regulatory news service, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it were tied to a specific reporting period. Since this is a specific scientific/clinical update rather than a standard quarterly financial release (ER) or a formal report (10-K, IR), and it is explicitly distributed via RNS, the most appropriate general category is RNS, as it is a regulatory announcement that doesn't fit the more specific categories like DIV, CAP, or ER. Given the structure (short announcement format, RNS header, focus on clinical trial results), it fits best under the general regulatory announcement category.
2021-09-09 English
ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH
Foreign Filer Report
2021-09-03 English
Ultomiris approved in EU for children with PNH
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 6162K' and contains information about a regulatory approval (Ultomiris approved in the EU) released on a specific date (03 September 2021) via a news service associated with the London Stock Exchange ('This information is provided by RNS, the news service of the London Stock Exchange.'). This structure is characteristic of a general regulatory announcement disseminated through the RNS system, which serves as a primary information provider for the UK market. Since the content is a specific press release about a drug approval and not a comprehensive financial report (like 10-K or IR) or a general announcement about publishing a report (RPA), the most appropriate classification is the general regulatory filing category, RNS.
2021-09-03 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2021-09-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a notification regarding 'Voting rights and capital' as of a specific date (31 August 2021), referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of announcement, which reports on the total number of voting rights, fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Although it relates to capital structure, it is a mandatory disclosure under transparency rules rather than a financing activity (CAP) or share issue (SHA). Given the source (RNS) and the nature of the disclosure (voting rights notification), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such mandatory regulatory updates.
2021-09-01 English
FORXIGA APPROVED IN JAPAN FOR CKD
Foreign Filer Report
2021-08-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.